Brief: Ascentage Pharma Group International Says Co Received Nod In U.S & China For Phase Ib/Ii Clinical Trials Of APG-2575
09/03/2020 10:31
March 9 (Reuters) - Ascentage Pharma Group International
6855.HK :
* RECEIVED APPROVALS IN U.S AND CHINA FOR PHASE IB/II
CLINICAL
TRIALS OF APG-2575 DEVELOPED BY CO
Source text for Eikon: ID:nHKS3QKWgC
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up